Table 1.

The characteristics of included trials

Study	Country of publication	Country of patients	Experimental Sample size	Control Sample Size	Age	Duration of diabetes	Intensive Therapy	Control therapy	Follow-up
Adrian F Hernandez 2018 [10]	USA	Western Europe Eastern and central Europe North America Latin America Asia Pacific	4731	4732	64.2/ 64.2	4.1/ 4.2	Albiglutide (30-50mg) once a week	Placebo once a week	1.5 years
Rury R. Holman 2017 [4]	United Kingdom	Europe, Latin America Europen subcategories, Asia-pacific, Eastern Europe, Western Europe, North America	7356	7396	<65y 8813 ≥65y 5939	12.0 (7.0-18.0)	exenatide at a dose of 2 mg once weekly	Placebo once a week	2.3 years
Steven P2016 [7]	USA	North AmericaEurope Asia Rest of the world	4668	4672	<60y 2321 ≥60y 7019	12.8 years	liraglutide 1.8 mg (or the maximum tolerated dose) once daily	placebo once daily	3.8 years
Steven P. Marso2016 [8]	United Kingdom	230 sites in 20 countries.	1648	1649	64.6± 7.4	13.9± 8.1	semaglutide (0.5mg or 1.0mg) once a week	Placebo once a week	109 weeks
Preffer MA 2015 [3]	Thailand	49 countrirs	3034	3034	60.3	9.3	lixisenatide	placebo	2.1 years
Gerstein HC 2019 [9]	UK	371 sites 24 countries	4949	4952	66.2	10.5/ 9.5	dulaglutide 1.5mg	placebo	5.4 years